{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wehrli M"],"funding":["DKMS Foundation","NIAID NIH HHS","Sociedad Española de Oncología Médica","National Institutes of Health","Swiss National Science Foundation","Deutsche Forschungsgemeinschaft","National Cancer Institute","NCI NIH HHS","Hopper-Belmont Foundation","American-Italian Cancer Foundation","NIGMS NIH HHS","CRIS Cancer Foundation","Italian Foundation for Cancer Research"],"pagination":["1859-1877"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11062832"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(9)"],"pubmed_abstract":["Purpose
Targeting solid tumors with chimeric antigen receptor (CAR) T cells remains challenging due to heterogenous target antigen expression, antigen escape, and the immunosuppressive tumor microenvironment (TME). Pancreatic cancer is characterized by a thick stroma generated by cancer-associated fibroblasts (CAF), which may contribute to the limited efficacy of mesothelin-directed CAR T cells in early-phase clinical trials. To provide a more favorable TME for CAR T cells to target pancreatic ductal adenocarcinoma (PDAC), we generated T cells with an antimesothelin CAR and a secreted T-cell-engaging molecule (TEAM) that targets CAF through fibroblast activation protein (FAP) and engages T cells through CD3 (termed mesoFAP CAR-TEAM cells).Experimental design
Using a suite o"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma."],"pmcid":["PMC11062832"],"funding_grant_id":["T32 AI007529","outback2021_6","DKMS-SLS-JHRG-2020-04","186739","466535590","T32 AI007247","K08CA226391","P400PM_186739","U01 CA228963","R01 CA238268","U01CA228963","R01 CA235412","R01CA235412","2T32AI007247-39","R01CA238268","K08 CA248710","T32 GM144273","K08CA248710","K08 CA226391"],"pubmed_authors":["Boland GM","Birocchi F","Larson RC","Korell F","Xu KH","Zhang R","Jaffee EM","Kuo A","Grauwet K","Scarfo I","Ting DT","Zheng L","Schmidts A","Maus MV","Anekal PV","Song Y","Leick MB","Montero Llopis P","Jan M","Choi BD","Jenkins RW","Nieman LT","Sun Y","Wehrli M","Burkhart RA","Berger TR","Kienka T","Guinn S","Silva H","Armstrong TD","Bouffard AA","Almazan AJ","Salas-Benito D","Fu J","Kann MC","Liss AS","Zhu Q","Bailey SR","Zimmerman JW"],"additional_accession":[]},"is_claimable":false,"name":"Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.","description":"Purpose
Targeting solid tumors with chimeric antigen receptor (CAR) T cells remains challenging due to heterogenous target antigen expression, antigen escape, and the immunosuppressive tumor microenvironment (TME). Pancreatic cancer is characterized by a thick stroma generated by cancer-associated fibroblasts (CAF), which may contribute to the limited efficacy of mesothelin-directed CAR T cells in early-phase clinical trials. To provide a more favorable TME for CAR T cells to target pancreatic ductal adenocarcinoma (PDAC), we generated T cells with an antimesothelin CAR and a secreted T-cell-engaging molecule (TEAM) that targets CAF through fibroblast activation protein (FAP) and engages T cells through CD3 (termed mesoFAP CAR-TEAM cells).Experimental design
Using a suite o","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2026-06-02T22:13:14.389Z","creation":"2025-04-06T14:25:50.919Z"},"accession":"S-EPMC11062832","cross_references":{"pubmed":["38393682"],"doi":["10.1158/1078-0432.CCR-23-3841","10.1158/1078-0432.ccr-23-3841"]}}